Industry support of CME down 17%

Share this article:
Total commercial support of accredited CME fell 17% to $856 million in 2009, according to ACCME's annual report—marking its second straight year of double-digit declines on a percentage basis.

For 2007, ACCME data showed commercial support increasing 1%. Sandwiched between 2008, when industry grants slid 14% to $1 billion, and a decade of sizable gains before it, 2007 proved to be the peak. The 2009 total also marks the first time since 2003 that industry funding dipped below $1 billion.

The number of physicians and non-physicians participating in CME stayed fairly flat in 2009, rising just 1% and 3%, respectively. The steady attendance figures—10.7 million doctors and 6.8 million non-physicians—proved to be a lone bright spot.

Total income reported by accredited providers fell 7.6% to $2.2 billion, while total expenses also decreased 11.9% to $1.7 billion. Providers actually faced higher fees and administrative work last year as they incorporated new transparency and measurement policies. The lower expenses could partly reflect attrition among ACCME-accredited providers: there are now 707 vs. 725 in 2008.

Both the number of certified CME activities and the number of hours of CME logged were also down in 2009, with activities declining 5.8% to 95,062 and hours plunging 10.4% to 689,768.

Industry grants, now accounting for 39% of total CME income vs. 56% in 2008, have taken a hit due to overall budget cuts by drug and device companies and the extreme scrutiny placed on industry-supported CME due to perceived bias.

Share this article:

Email Newsletters

More in News

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.

GSK, Novartis, Lilly play musical chairs

GSK, Novartis, Lilly play musical chairs

The three drugmakers rearranged part of the pharma universe Tuesday with a string of pipeline-altering deals.

Valeant bids $47B for Allergan

Valeant bids $47B for Allergan

The deal would bring Allergan's Botox and Juvederm under the same roof as Restylane.